Literature DB >> 18175894

A potent hypotensive peptide, novokinin, induces relaxation by AT2- and IP-receptor-dependent mechanism in the mesenteric artery from SHRs.

Yuko Yamada1, Daiki Yamauchi, Megumi Yokoo, Kousaku Ohinata, Hachiro Usui, Masaaki Yoshikawa.   

Abstract

In this study, we found that novokinin (Arg-Pro-Leu-Lys-Pro-Trp), a potent hypotensive peptide acting through the AT(2) receptor, has vasorelaxing activity in the mesenteric artery isolated from spontaneously hypertensive rats. The vasorelaxing activity was significantly blocked by PD123319, indomethacin, and CAY10441, which are an AT(2) receptor antagonist, a cyclooxygenase inhibitor, and an IP receptor antagonist, respectively. N(G)-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthase, did not block the vasorelaxing activity. These results suggest that the vasorelaxing activity of novokinin, which contributes to the hypotensive effect, is mainly mediated by prostaglandin I(2) (prostacyclin) and the IP receptor downstream of the AT(2) receptor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18175894     DOI: 10.1271/bbb.70638

Source DB:  PubMed          Journal:  Biosci Biotechnol Biochem        ISSN: 0916-8451            Impact factor:   2.043


  5 in total

1.  Role of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in airway reactivity and inflammation in an allergic mouse model of asthma.

Authors:  Mehaben Patel; Mangesh Kurade; Sahith Rajalingam; Riya Bhavsar; S Jamal Mustafa; Dovenia S Ponnoth
Journal:  Immunopharmacol Immunotoxicol       Date:  2019-05-07       Impact factor: 2.730

2.  Protective effects of losartan on some type 2 diabetes mellitus-induced complications in Wistar and spontaneously hypertensive rats.

Authors:  Daniela Pechlivanova; Ekaterina Krumova; Nedelina Kostadinova; Jeny Mitreva-Staleva; Petar Grozdanov; Alexander Stoynev
Journal:  Metab Brain Dis       Date:  2020-01-29       Impact factor: 3.584

Review 3.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

4.  Preserved arterial vasodilatation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice.

Authors:  Satomi Kagota; Elizabeth Chia; John J McGuire
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

5.  Bone-Targeted Delivery of Novokinin as an Alternative Treatment Option for Rheumatoid Arthritis.

Authors:  Arina Ranjit; Sana Khajeh Pour; Ali Aghazadeh-Habashi
Journal:  Pharmaceutics       Date:  2022-08-12       Impact factor: 6.525

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.